menu
    • menu
    [{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Acousia Therapeutics

    Menu

    Acousia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acousia Therapeutics

                            Germany arrow
                            EASL Congress
                            Not Confirmed

                            Acousia Therapeutics

                            Germany arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACOU085

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hearing Loss Company Acousia Therapeutics to Present Data for Lead Candidates ACOU085 & ACOU082 at ARO 2023 Mi...

                            Details : ACOU085 is a proprietary small molecule, etiology-agnostic otoprotective drug candidate, expected to finish a first-in-man clinical Phase 1b study by late 2022 using standard transtympanic administration of a slow-release gel formulation.

                            Product Name : ACOU085

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 24, 2022

                            Lead Product(s) : ACOU085

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acousia Therapeutics

                            Germany arrow
                            EASL Congress
                            Not Confirmed

                            Acousia Therapeutics

                            Germany arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACOU085

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Acousia Therapeutics to Present Its First-in-class Hearing Loss Treatment Program With ACOU085 at the 2nd Inne...

                            Details : ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients.

                            Product Name : ACOU085

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 05, 2022

                            Lead Product(s) : ACOU085

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Acousia Therapeutics

                            Germany arrow
                            EASL Congress
                            Not Confirmed

                            Acousia Therapeutics

                            Germany arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACOU085

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hearing Loss Company Acousia Therapeutics: First Patient With Age-related Hearing Loss Treated With ACOU085

                            Details : ACOU085 is a proprietary small-molecule, otoprotective drug candidate that modulates a well-defined molecular target preferentially expressed in the sensory cells of the inner ear, the so-called outer hair cells (OHC).

                            Product Name : ACOU085

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 05, 2022

                            Lead Product(s) : ACOU085

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth